would have thought the nature medicine study should indicate that Parsortix could be most useful for monitoring post-op in women without evidence of metastatic disease especially those at higher risk for metastases, rather than in the metastatic setting where the existence of tumour cell clusters adds little value except to guide drug therapy. There again, even seemingly low risk patients can develop metastatic disease; the survival curves continue to diverge for 30 or more years in breast cancer compared with non-sufferers. Late metastasis/scar recurrence 15 years or more post surgery is not that uncommon. Begs the question of where the cells have been all that time? some suggest micrometastases/isolated tumour cells lie dormant in the bone marrow and are reactivated by some unknown trigger.
So, Parsortix could find a role in all women post-op without evidence of metastatic disease for monitoring. problem is cash burn. |
https://www.proactiveinvestors.com.au/companies/news/1065008/angle-plc-says-nature-medicine-journal-highlights-parsortix-s-role-in-cancer-breakthrough-1065008.html |
Building up momentum for a confirmed* breakout of the 200 day MA
free stock charts from uk.advfn.com
* Usually technical analysts will look for secondary indicator clues as to strength and conviction of breakout such as volume, 2 consecutive days close above the level and a retest of resistance as support |
Imagine bones walking along the pavement and kicking cats in the belly when no one is looking. |
Multibavger your clueless . Still don't get the difference between cash runway and what is needed to avoid a going concern qualification . Like many on this BB over the years very clued up on the science but when it comes to business and accounts sadly very lacking . The fund raises have kept coming as I predicted many many years ago,even when the bod and plenty of investors said they wouldn't . One more incoming imo before may watch this space |
Next week the share price will build strongly towards 17p
After we sign another contract or two we will easily be trading in the 20s
sent from my iPhone |
A clearer version.. |
Icopied and pasted the link no problem, thanks mesquida. Although I would not describe the rise as a "Surge". |
Lofty, this is not a link so cannot access the article, in a few brief words can you tell us what it says. Thanks in advance. |
https://i.dailymail.co.uk/1s/2025/01/24/21/94489731-14322641-image-a-11_1737753553374.jpg |
A while ago whilst responding to a question about the future of the company Andrew said one of three things will happen.1. Angle will become a large company 2. Angle will partner with a large company3. Angle will be bought by a large company.Think on that one. |
That is very vague. It could be Q1 in 2026.
The trading update in November 2023 stated we had a cash runway to Q2 2025.
By the beginning of June 2024 we had a cash call for 8.5 million and possible 2,000,000 to shareholders of which only half of a million was raised.
This was done as a 16.7% discount to the prevailing price, and 10 to 12 months before the cash runway was supposed to expire.
Think on that one. |
Cash runway till 2026 bone-idle. |
 waterloo01 - you may be right, personally I hope not but time will tell. UK Small Cap success stories are indeed historically speaking, a bit thin on the ground & by that I mean those that develop within the UK & continue to grow.
There are plenty of signs that Angle are forging strong relationships as perhaps can be illustrated here :
'Complementary insights: Exploring the dual analysis of circulating tumour cells and circulating DNA' EACR-Illumina webinar
Thursday 06 February 2025 | 17:00 – 18:00 CET
This public webinar is hosted in collaboration with Illumina, one of our valued EACR Industry Partners. In this webinar, Anne-Sophie Pailhes-Jimenez will present dual analysis data from samples taken from lung cancer patients and she will discuss how dual analysis of liquid biopsy analytes may hold potential to capture a more comprehensive picture of tumour heterogeneity and ultimately inform personalised cancer care.
Click here to register (open to all, you do not need to be an EACR member to attend)."
Anne-Sophie Pailhes-Jimenez |
Someone, ie Illumina or Quigen or AZ will make them an offer. Long thought it... |
Decent volume today. Primarily on the back of the latest rns.
More to come and I suspect it'll continue to be a combination of new or extended contracts as well as trial results.
Interesting times that's for sure. |
Bones....maybe lauch another aliasIdea...bone idle. |
Lovely bowl chart forming over the 1 year So far we have these figures for the share price:Up 22% in 7 daysUp 40% on the monthUp 81% over 3 months |
Don't mind bones
He's still short
The next contract should be enough to squeeze him out at a hefty loss
sent from my iPhone |
Remember when adw sold all his shares thinking he was clever
Then we had PATT bones and all the other cronies talking the company down
What happened next? We saw 25p very quickly
History repeating
sent from my iPhone |
Cash runway to 2026. What are you on about bones?? |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
